-
Clasto-Lactacystin β-lactone: Precision Proteasome Inhibitio
2026-06-10
Clasto-Lactacystin β-lactone delivers irreversible, highly specific proteasome inhibition—empowering researchers to dissect protein turnover, cell death, and immune pathways in cancer and viral inflammation studies. Discover experimental workflows and troubleshooting guidance that unlock its full utility for advanced ubiquitin-proteasome pathway research.
-
CD36-Mediated Lipid Metabolism Drives Immune Escape in AML
2026-06-10
Guo et al. reveal that CD36 on AML cells orchestrates a non-canonical lipid metabolism program, facilitating immune evasion and resistance to hypomethylating agent therapy. Their findings highlight a metabolic-immune axis in acute myeloid leukemia, with implications for improving therapeutic strategies by targeting CD36 signaling.
-
Paroxetine Mesylate: Multi-Target SSRI for Advanced Research
2026-06-09
Paroxetine Mesylate stands apart as a selective serotonin reuptake inhibitor with demonstrated utility in both neuropharmacology and oncology. Its multi-target activity—including inhibition of SERT, key cytochrome P450 isozymes, and receptor tyrosine kinases—delivers versatility for translational workflows from psychiatric models to anti-colorectal cancer assays.
-
Technical Guide: Hematoxylin and Eosin Staining Kit (K1142)
2026-06-09
The Hematoxylin and Eosin Staining Kit (K1142) offers ready-to-use solutions for reliable tissue morphology visualization in research settings, supporting paraffin-embedded, frozen, and cytological preparations. This kit streamlines the workflow for nuclear and cytoplasmic staining but is not validated for diagnostic or clinical use and should only be used in controlled research environments.
-
SB 202190: Precision p38 MAP Kinase Inhibitor in Cancer Rese
2026-06-08
SB 202190 enables selective, ATP-competitive inhibition of p38α/β MAPKs, empowering advanced workflows in inflammation and cancer therapeutics research. This article details rigorous protocols, troubleshooting insights, and groundbreaking use-cases, including the latest high-content screening innovations for dissecting ECM-driven cancer cell migration.
-
2-APB: Precision Control of Calcium Signaling in Cell Fate R
2026-06-08
2-APB (2-aminoethoxydiphenyl borate) empowers researchers to dissect the interplay between autophagy and apoptosis by selectively inhibiting IP3R-mediated calcium release. Its practical advantages in dynamic cell fate studies, especially under stress models, set it apart for mechanistic interrogation and experimental refinement.
-
M344 Histone Deacetylase Inhibitor: Applied Workflows in Can
2026-06-07
M344 is a potent, cell-permeable histone deacetylase inhibitor that enables researchers to dissect epigenetic regulation and suppress tumor proliferation in challenging models such as breast cancer and neuroblastoma. This guide details actionable protocols, troubleshooting insights, and real-world workflow enhancements for maximizing reproducibility and impact using M344 from APExBIO.
-
Carrier-Platin: Accelerating Cancer Cell Death via ROS Storm
2026-06-06
A recent study introduces carrier-platin, a platinum-based nanodrug that triggers a rapid and overwhelming burst of intracellular reactive oxygen species (ROS), leading to swift and non-classical cancer cell death. This innovation advances ROS-driven chemotherapeutic strategies and may overcome resistance in hard-to-treat tumors.
-
Eicosapentaenoic Acid: Applied Workflows in Cardiovascular R
2026-06-05
Eicosapentaenoic Acid (EPA), a high-purity omega-3 fatty acid from APExBIO, delivers reproducible outcomes in cardiovascular and immunometabolic research. This article details experimental workflows, protocol parameters, and troubleshooting strategies that maximize EPA’s anti-inflammatory and lipid-lowering effects for reliable, high-impact data.
-
Malate in Tumor Immunometabolism: Mechanistic Rationale to T
2026-06-05
This article explores the strategic integration of malate ((S)-2-hydroxysuccinic acid) in translational research, spotlighting its role in metabolic and immunological crosstalk within the tumor microenvironment. Drawing on recent mechanistic discoveries in cholangiocarcinoma, it provides actionable insights and protocol guidance for researchers investigating TCA cycle intermediates, with APExBIO’s malate highlighted for experimental rigor.
-
A40926: Regulatory Engineering and Next-Gen Antibacterial As
2026-06-04
Explore how A40926, a potent dalbavancin precursor, is reshaping antibiotic research through regulatory pathway engineering and advanced antibacterial assays. This article uniquely examines biosynthetic optimization and translational implications for Gram-positive and multidrug-resistant pathogens.
-
Clasto-Lactacystin β-lactone: Catalyzing Translational Disco
2026-06-04
This thought-leadership article explores how Clasto-Lactacystin β-lactone, a potent, irreversible, and cell-permeable proteasome inhibitor, empowers translational researchers to unravel complex disease mechanisms and model therapeutic interventions. By integrating mechanistic insights, recent immunology findings, and strategic guidance, the article charts a clear roadmap for leveraging this compound across cancer, neurodegeneration, and host-pathogen research, while addressing maturity, limitations, and future outlook.
-
M344 (SKU A4105): Scenario-Driven Solutions in Epigenetic As
2026-06-03
This article addresses real-world challenges in cell viability, proliferation, and cytotoxicity assays by showcasing how M344 (SKU A4105), a potent histone deacetylase inhibitor, empowers biomedical researchers with reproducible, data-backed experimental outcomes. Drawing on validated parameters and scenario-driven analysis, we demonstrate the reliability and versatility of M344 for advanced cancer and HIV latency research.
-
3-Aminobenzamide: Bridging PARP Inhibition and Translational
2026-06-03
This thought-leadership article examines how 3-Aminobenzamide (PARP-IN-1) is redefining poly (ADP-ribose) polymerase inhibition for translational research. By integrating mechanistic insights, experimental best practices, and the latest evidence from antiviral and metabolic disease domains, we provide actionable guidance for researchers seeking robust, reproducible, and forward-thinking PARP modulation strategies.
-
HDAC2-Regulated Spliceosome Acetylation Sensitizes HCC to PA
2026-06-02
This study uncovers how HDAC2-mediated deacetylation of the core spliceosome component SmD2 stabilizes its protein levels, affecting alternative splicing and DNA repair in hepatocellular carcinoma (HCC). Disruption of this axis sensitizes HCC cells to PARP inhibitors, and combining Romidepsin (an HDAC inhibitor) with Olaparib yields strong therapeutic effects in preclinical models.